CLINICAL EVALUATION OF CEFOTIAM THERAPY IN CHILDREN

Cefotiam (CTM) was evaluated for its safety and efficacy in children. Twenty-six patients were treated with 40 to 200 mg/kg per day of CTM by intravenous administrations. The diagnosis of the patients were acute pharyngitis (2), acute bronchitis (1), pneumonia (4), empyema (2), urinary tract infecti...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of antibiotics 1981/05/25, Vol.34(5), pp.711-718
Main Authors: MEGURO, HIDENORI, MASHIKO, JIN, OZAWA, SHIN-ICHI, MATSUEDA, YORIKO, FUJII, RYOCHI
Format: Article
Language:Japanese
Subjects:
Age Factors
Anti-Bacterial Agents - adverse effects
Anti-Bacterial Agents - metabolism
Anti-Bacterial Agents - therapeutic use
Bacterial Infections - drug therapy
Campylobacter jejuni
Cefotaxime - adverse effects
Cefotaxime - analogs & derivatives
Cefotaxime - metabolism
Cefotaxime - therapeutic use
Cefotiam
Child
Child, Preschool
Drug Evaluation
Escherichia coli
Female
Haemophilus influenzae
Humans
Infant
Infant, Newborn
Injections, Intravenous
Male
Salmonella typhi
Streptococcus pneumoniae
Streptococcus pyogenes
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cefotiam (CTM) was evaluated for its safety and efficacy in children. Twenty-six patients were treated with 40 to 200 mg/kg per day of CTM by intravenous administrations. The diagnosis of the patients were acute pharyngitis (2), acute bronchitis (1), pneumonia (4), empyema (2), urinary tract infection (2), typhoid fever (1), acute enterocolitis (2), partially-treated purulent meningitis (1), and suspected septicemia in neuroblastoma (1); and the remaining ten patients were considered to have nonbacterial infections. The pathogens recovered were Streptococcus pyogenes(1),Streptococcus pneumoniae(1),Staphylococcus aureus(4),Haemophilus influenzae(4),Escherichia coli(1) enteropathogenic Escherichia coli(1),Salmonella typhi(1) and Campylobacter jejuni(1). All but two patients of bacterial infections were cured after the CTM therapy, and the rate of efficacy was 87.5%. Diarrhea (3), urticaria (1), transient elevation of GOT and GPT (1), and transient eosinophilia (3) were found to be associated with the CTM therapy. However, no severe adverse reactions were encountered. Half life of the serum CTM level was 0.93±0.13 hours, and excretion into the urine was rapid. CSF concentration obtained 1 hour after an intravenous injection of 21 mg/kg of CTM in a case with inflamed meninges was 1.5 mcg/ml, and the CSF/serum ratio was 9.0%. From these data, CTM appears to be a safe and effective antibiotic when used in children with susceptible bacterial infections.
ISSN:0368-2781
2186-5477
DOI:10.11553/antibiotics1968b.34.711